Dihydromyricetin Reduced Bcl-2 Expression via p53 in Human Hepatoma HepG2 Cells

• Published in: PloS one Vol. 8; no. 11; p. e76886
• Main Authors: Wu, Shixing, Liu, Bin, Zhang, Qingyu, Liu, Jie, Zhou, Wei, Wang, Chang, Li, Mingyi, Bao, Shiting, Zhu, Runzhi
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 04.11.2013; Public Library of Science (PLoS)
• Subjects: Analysis; Anticancer properties; Antineoplastic Agents - pharmacology; Antitumor activity; Apoptosis; BAX protein; Bcl-2 protein; bcl-2-Associated X Protein - genetics; bcl-2-Associated X Protein - metabolism; Bromine compounds; Cell cycle; Cell Proliferation - drug effects; Cytotoxicity; Down-Regulation - drug effects; Drug Screening Assays, Antitumor; Flavonoids; Flavonols - pharmacology; Gene expression; Hep G2 Cells; Hepatocellular carcinoma; Hepatoma; Humans; Kinases; Laboratories; Leukemia; Liver cancer; Medicine; p53 Protein; Prostate cancer; Proto-Oncogene Proteins c-bcl-2 - genetics; Proto-Oncogene Proteins c-bcl-2 - metabolism; Ribonucleic acid; RNA; Signal Transduction; Silence; siRNA; Surgery; Tumor proteins; Tumor Suppressor Protein p53 - physiology; Viability; Wu, Bin; China

Dihydromyricetin (DHM) is a major active ingredient of flavonoids compounds. It exhibited anticancer activity and induced apoptosis in human hepatocellular carcinoma HepG2 cells according to our previous data. In this study, we investigated whether p53 is involved in DHM-triggered viability inhibiti...